This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1 Sep 2021

Aptar Pharma Granted Exclusive License Option by Pharmaxis to Develop and Promote High Payload Dry Powder Inhaler

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that they have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital.

Agreement gives Aptar Pharma an exclusive 12-month option to acquire worldwide rights to Pharmaxis’ proprietary “Orbital” technology, which delivers large payloads of drug in a convenient, easy-to-use format.

Mentioned Companies
Aptar Pharma
View company profile